PD-1/PD-L1 blockade
PreclinicalSmall molecule
PD-1/PD-L1 blockade is one of 21 small molecule programs targeting Metastatic Non Small Cell Lung Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Metastatic Non Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
DATROWAY
Daiichi SankyoPhase 3
Koselugo
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-1/PD-L1 blockade. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TThomas Marron